Barclays PLC Brainstorm Cell Therapeutics Inc. Transaction History

Barclays PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	BUY	$0.15 - $0.4 $3,469 - $9,251	23,128 New	23,128 $6,000
Q4 2021 Feb 14, 2022	SELL	$2.81 - $4.23 $11,990 - $18,049	-4,267 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$3.14 - $4.09 $11,683 - $15,218	-3,721 Reduced 46.58%	4,267 $14,000
Q2 2021 Aug 13, 2021	SELL	$3.01 - $4.01 $52,711 - $70,223	-17,512 Reduced 68.67%	7,988 $31,000
Q1 2021 May 13, 2021	BUY	$3.46 - $7.88 $58,162 - $132,462	16,810 Added 193.44%	25,500 $98,000
Q4 2020 Feb 11, 2021	SELL	$3.99 - $17.73 $17,516 - $77,834	-4,390 Reduced 33.56%	8,690 $39,000
Q3 2020 Nov 12, 2020	SELL	$11.19 - $16.92 $17,758 - $26,852	-1,587 Reduced 10.82%	13,080 $221,000
Q2 2020 Aug 12, 2020	BUY	$4.42 - $12.66 $64,828 - $185,684	14,667 New	14,667 $164,000
Q1 2020 May 13, 2020	SELL	$4.01 - $8.88 $12 - $26	-3 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$3.62 - $4.29 $10 - $12	3 New	3 $0
Q2 2018 Aug 14, 2018	SELL	$3.12 - $5.19 $3 - $5	-1 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$3.01 - $3.77 $3 - $3	1 New	1 $0

10.8M

160K

30.5K

Ticker BCLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,486,200
Market Cap $83.2M
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.